工程化神经介素U促进2型先天免疫并保护急性肾损伤肾脏
在缺血再灌注诱导的急性肾损伤小鼠模型中,预防性给予工程化神经介素U类似物LIMM102可降低死亡率、提高肾小球滤过率、减少肾损伤标志物和病变严重程度,并伴随肾脏2型先天淋巴样细胞活化;这些保护作用完全依赖神经介素U受体1信号。
要点
- LIMM102在体外和体内均增强肾脏2型先天淋巴样细胞活化。
- LIMM102通过激活肾脏2型先天淋巴样细胞降低急性肾损伤模型死亡率并改善肾功能。
- LIMM102的肾脏保护作用依赖神经介素U受体1,提示该轴为急性肾损伤治疗新靶点。
核心结论
- LIMM102通过神经介素U受体1改善缺血再灌注诱导的急性肾损伤肾功能,该作用与肾脏中活化的2型先天淋巴样细胞相关。
研究设计与样本
- 临床前研究:野生型小鼠接受缺血再灌注诱导的急性肾损伤并预防性给予LIMM102,设假手术对照;另用神经介素U受体1缺陷小鼠(Nmur1−/−)验证信号依赖性。
主要发现
- LIMM102治疗的缺血再灌注动物死亡率低于未治疗的缺血再灌注对照。
- LIMM102治疗动物肾小球滤过率更高、肾功能生物标志物水平更低、肾脏病变严重程度更低,并与肾脏2型先天淋巴样细胞活化表型相关。
- 在Nmur1缺陷动物中,LIMM102对急性肾损伤结局未产生有益效应,表明其治疗作用完全依赖神经介素U受体1信号。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
KEY POINTS: Engineered Neuromedin U (LIMM102) had augmented efficacy in activating renal type 2 innate lymphoid cells (ILC2) both in vitro and in vivo. LIMM102 reduced mortality and enhanced kidney function in a model of AKI by activating renal ILC2s. The renoprotective effects of LIMM102 were neuromedin U receptor 1–dependent, highlighting the ILC2-neuromedin U receptor 1 axis as a novel therapeutic target for AKI therapy. BACKGROUND: AKI is a severe condition leading to the sudden loss of kidney function. Activation of type 2 innate lymphoid cells (ILC2s) by neuromedin U (NMU) is highly selective and key in controlling mucosal tissue repair and homeostasis. Renal ILC2s are associated with renoprotective effects in AKI. Here, we explored the therapeutic potential of an engineered NMU analogue (LIMM102) in a preclinical model of renal ischemia-reperfusion injury (IRI)–induced AKI. METHODS: LIMM102 was administered prophylactically to wild-type mice subjected to IRI-induced AKI and to Sham-operated controls. Survival, GFR, kidney function biomarkers, histopathologic analysis, and immune cell infiltration were assessed to determine LIMM102 treatment efficacy. Moreover, to interrogate the molecular selectivity of LIMM102, NMU receptor 1 (NMUR1)–deficient mice (Nmur1−/−) were used to formally test the need of NMUR1 signaling for the beneficial effects of LIMM102. RESULTS: LIMM102-treated IRI animals presented lower mortality rates when compared with their untreated IRI counterparts. Notably, LIMM102-treated animals displayed higher GFR, lower levels of kidney function biomarkers, and lower severity of kidney lesions, which associated with renal ILC2-activated phenotypes. Importantly, LIMM102 therapeutic effects relied entirely on NMUR1 signaling, as LIMM102 administration produced no beneficial effect on AKI outcome in Nmur1-deficient animals. CONCLUSIONS: LIMM102 exerted its therapeutic action by improving kidney function in IRI-induced AKI via NMUR1, which was associated with the presence of activated ILC2s in the kidney.
引用
- Trindade-Correia S, Correia V, Delgado F, et al. Engineered Neuromedin U Promotes Type 2 Innate Immunity and Renoprotection in Acute Kidney Injury. J Am Soc Nephrol. 2025. PMID: 40338728. doi:10.1681/ASN.0000000747
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。